DTPA (pentetic acid) Disease Interactions
There are 2 disease interactions with DTPA (pentetic acid):
Pentetic acid (Includes DTPA) ↔ renal dysfunction
Moderate Potential Hazard, Moderate plausibility. Applies to: Renal Dysfunction
The image quality obtained with Technetium Tc 99m pentetate may be adversely affected by impaired renal function. Literature reports indicate that the target to non-target ratio for intracranial lesions may take several hours to develop fully, thus the possibility of missing certain lesions when imaging is restricted to the early period after injection should be recognized.
Technetium Tc 99m bicisate/exametazime/pentetate (Includes DTPA) ↔ renal dysfunction
Moderate Potential Hazard, High plausibility. Applies to: Renal Dysfunction
Technetium Tc 99m conjugates (e.g., bicisate, exametazime, pentetate) are often eliminated by the kidney, and the risk of toxic reactions to these drugs may be greater in patients with impaired renal function. Dosage adjustments have not been studied in patients with renal and/or hepatic impairment. Caution is advised when used in these patients.
Drug Interaction Classification
|Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit.|
|Moderately clinically significant. Usually avoid combinations; use it only under special circumstances.|
|Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan.|
|No interaction information available.|
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.